ArticleSleep advances : a journal of the Sleep Research Society2026
Effects of lemborexant and zolpidem on sleep electroencephalography in older adults with insomnia: a randomized trial.
Article in Sleep advances : a journal of the Sleep Research Society, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
How sleep medications affect brain physiology over time remains largely unknown. Prior pharmacodynamic work has established distinct spectral signatures of GABA-A receptor modulators vs. DORAs in younger or mixed adult samples. Here, we report how sleep EEG effects evolve from acute (days 1-2) to chronic (days 29-30) exposure in older adults with insomnia meeting DSM-5 criteria, and how within-person changes relate to Insomnia Severity Index (ISI). This analysis used data from a randomized, double-blind, placebo-controlled, active-comparator phase III trial (May 2016-January 2018). A subset of 249 participants was analyzed for EEG outcomes. Participants received 5 mg or 10 mg LEM (LEM5, LEM10), 6.25 mg extended-release zolpidem (ZOL), or placebo nightly for 30 days. Polysomnography was collected at baseline, after acute exposure, and after chronic exposure. Acute ZOL exposure produced significant increases in non-rapid eye movement (NREM) slow oscillation (SO), sigma, beta, and gamma power, with decreases in delta and theta compared to all treatment groups. These effects persisted with chronic exposure, alongside an alpha increase from acute to chronic exposure. LEM10 showed minimal acute effects but, with continued use, increased SO and decreased alpha power. The degree of SO power increase from acute to chronic exposure predicted improvements in ISI scores, driven by the LEM10 group. ZOL showed similar REM effects, whereas LEM5, but not LEM10, reduced REM sigma and beta power. These findings demonstrate that ZOL and LEM differentially modulate sleep EEG, with sustained SO enhancement under LEM10 linked to symptom improvement.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.